AV can bring efficiency, savings, quality

Beth Walsh - FOR LEAD ONLY - 195.12 Kb
Beth Walsh, Editor, CMIO
The latest studies related to advanced visualization show how new technology is bringing home the ideal trifecta of reduced costs, improved efficiency and better quality of care and outcomes.

For example, an automated lung nodule matching program can improve radiologists’ efficiency almost two-fold, according to a study published in the July issue of American Journal of Roentgenology.

Serial CT assessment and comparison of pulmonary nodules has been a manual, time-consuming process. The advent of automated lung nodule matching software may offer a new model to improve diagnostic performance and efficiency.

In the study, four thoracic radiologists manually identified and matched 325 pulmonary nodules identified on CT and six weeks later evaluated the same CT studies using the automated nodule matching software. The time required for manual nodule matching ranged from one second to approximately 11.4 minutes, whereas automated nodule matching ranged from less than one second to approximately 6.6 minutes.

The software provided high accuracy and delivered match rates of 90 percent for two readers and 79 percent and 92 percent for the remaining two radiologists.

Another study, published in Radiology, found that MRI utilizing ultrasmall superparamagnetic iron oxide (USPIO) particles in combination with the current standard of a gadolinium-based contrast agent enabled detection of more than 50 percent more multiple sclerosis (MS) lesions than imaging with gadolinium alone.

Enhancement with a gadolinium-based contrast agent is the primary sign of MS disease activity, and it indicates accumulation of the agent due to increased blood-brain barrier permeability. This approach, however, is nonspecific and lacks sensitivity.

To test the benefit of USPIO-enhanced MR exams, the researchers studied 24 patients with MS using gadolinium- and USPIO-enhanced MRI at baseline and six-month follow-up. Results showed that 37 lesions were considered active owing to gadolinium-based enhancement at baseline. The addition of USPIO helped detect 19 additional lesions, a 51 percent increase compared with gadolinium alone.

I find these kinds of results so encouraging—anything to help clinicians find the full problem and do so more quickly is a wonderful step in the right direction. Are your clinicians and IT teams prepared to integrate these practices and software?

Beth Walsh
CMIO Editor
bwalsh@trimedmedia.com

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.